Pasithea Therapeutics (NASDAQ:KTTA) Issues Earnings Results

Pasithea Therapeutics (NASDAQ:KTTA) announced its quarterly earnings data on Monday. The company reported ($2.41) earnings per share for the quarter, Zacks reports.

Pasithea Therapeutics Stock Performance

Pasithea Therapeutics stock opened at $1.25 on Wednesday. The stock’s 50 day moving average price is $1.65 and its 200 day moving average price is $2.93. Pasithea Therapeutics has a 1-year low of $0.92 and a 1-year high of $9.25.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.